(NASDAQ: AFFX) today announced the expansion of its license agreement with Siemens Healthcare Diagnostics for the company’s branched DNA (bDNA) technology whereby Affymetrix is the exclusive licensee ...
Mindy Lee-Olsen, 408-731-5523 (Media)Vice President, Marketing ServicesorDoug Farrell, 408-731-5285 (Investors)Vice President, Investor Relations (NASDAQ:AFFX) announced today the availability of ...
OXFORD, England--(BUSINESS WIRE)--Cytox Ltd, an innovative developer of assays for risk assessment and prediction of dementia, and Affymetrix (Nasdaq:AFFX), a leading provider of translational ...
Affymetrix adds complementary products in genetic analysis that are used in cytogenetics, genotyping and gene expression. The company’s innovative microarray platform will strengthen Thermo Fisher’s ...
SANTA CLARA, Calif. and WASHINGTON, June 3 -- Affymetrix, Inc. (Nasdaq: AFFX) and the American Association for the Advancement of Science (AAAS) today announced Affymetrix' support of the AAAS Newcomb ...
Offerings Now Encompass Multiplex and Parallel Analysis of Cells, Proteins, and Genes Affymetrix, best known for its pioneering work in commercializing microarrays for gene expression research since ...
Unique and optimized solution provides highly sensitive and reproducible RNA amplification and labeling from archived FFPE samples for biomarker discovery and validation on industry-leading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results